Hi Sergio
Hier ist noch ein Kandidat
FDA Clinical Phase: 2
Description:
Carfilzomib, which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies have shown that carfilzomib has an encouraging safety profile, with low levels of neuropathy (a common side effect for many myeloma treatments). A Phase 2 trial with relapsed and refractory myeloma patients has recently closed enrollment, and results are expected in late 2010.
Found 4 studies with search of: carfilzomib myeloma | Open Studies
Include studies that are not seeking new volunteers.
Display Options
Rank Status Study
1 Recruiting Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
Conditions: Multiple Myeloma; Renal Insufficiency
Intervention: Drug: Carfilzomib for Injection, PR-171
2 Recruiting Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma
Condition: Relapsed Multiple Myeloma
Intervention: Drug: Carfilzomib with Lenalidomide and Dexamethasone
3 Recruiting Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma
Conditions: Ovarian Cancer; Renal Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Multiple Myeloma
Intervention: Drug: carfilzomib
4 Recruiting Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: carfilzomib
&&&&&&&&&&&
Kommt Zeit .......................kommen Medis !!!!!!!!!
Liebe Grüsse
Joseph
